skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

46 Total results for product and free and sample content found

Generics Bulletin

Celltrion's Remsima SC Ready For Early 2020 Launch

By David Wallace 27 Nov 2020

Article

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Topic Biosimilars Launches Regulation

Datamonitor Healthcare

The evolving landscape of biosimilars

27 Nov 2020

The evolving landscape of biosimilars

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Topic Biosimilars

Generics Bulletin

Alberta Is Second Canadian Province To Switch To Biosimilars

By David Wallace 27 Nov 2020

Alberta_Is_Second_Canadian_Province_To_Switch_1

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Topic Biosimilars Regulation

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Pink Sheet

Germany Sets Direction Of Travel With New Biosimilar Guidelines

By Francesca Bruce 21 Sep 2020

Biosimilars Germany

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Topic EU Biosimilars

Chemist + Druggist Data

UK Sees PIP Codes Expand To Cover Hospital Drugs

By C+D Data 09 Sep 2020

Pharmacists PIP Code Expansion

Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital drugs.

Topic BioPharmaceutical Regulation Biosimilars

Generics Bulletin

Teva Debuts US Rituximab At A 10% Discount

By David Wallace 08 Nov 2019

Article

Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

Topic Biosimilars Strategy

Custom Intelligence Biosimilars Whitepaper

By Duncan Emerton 04 Nov 2019

Custom Intelligence Biosimilars Whitepaper

If you’re looking at the opportunities to increase revenue and mitigate current and future threats by formulating the strongest biosimilars strategy, Informa’s Biosimilars Insights and Analysis Service is the tool you need.

Topic Biosimilars

Generics Bulletin

Sandoz Reveals Biosimilar Denosumab Program

By David Wallace 30 Jul 2019

Sandoz Reveals Biosimilar Denosumab Program

As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.

Topic Company Analysis Biosimilars

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: